Antonio Finelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9111869/publications.pdf

Version: 2024-02-01

210 papers	5,649 citations	101535 36 h-index	106340 65 g-index
215 all docs	215 docs citations	215 times ranked	8627 citing authors

#	Article	IF	Citations
1	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
2	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
3	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 668-680.	1.6	262
4	Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature, 2020, 586, 120-126.	27.8	249
5	Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. European Urology, 2015, 68, 1007-1013.	1.9	238
6	Landmarks in the diagnosis and treatment of renal cell carcinoma. Nature Reviews Urology, 2014, 11, 517-525.	3.8	176
7	International Urology Journal Club via Twitter: 12-Month Experience. European Urology, 2014, 66, 112-117.	1.9	143
8	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. Journal of Clinical Oncology, 2018, 36, 3251-3258.	1.6	129
9	Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4 cm Can Be Offered Active Surveillance as an Initial Management Strategy. European Urology, 2016, 70, 85-90.	1.9	105
10	Comparison of Multiparametric Magnetic Resonance Imagingâ€“Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. JAMA Oncology, 2021, 7, 534.	7.1	99
11	Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. European Urology, 2015, 67, 64-70.	1.9	91
12	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. Journal of Urology, 2015, 193, 1519-1524.	0.4	90
13	Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Journal of Clinical Oncology, 2014, 32, 3892-3898.	1.6	84
14	Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial. Surgical Oncology, 2018, 27, 289-298.	1.6	83
15	Active Surveillance for Renal Neoplasms with Oncocytic Features is Safe. Journal of Urology, 2016, 195, 581-587.	0.4	77
16	Use of In-Biofilm Expression Technology To Identify Genes Involved in Pseudomonas aeruginosa Biofilm Development. Journal of Bacteriology, 2003, 185, 2700-2710.	2.2	70
17	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. Urology, 2016, 94, 154-160.	1.0	60
18	Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?. Journal of Urology, 2018, 200, 731-736.	0.4	60

#	Article	IF	Citations
19	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. European Urology, 2014, 66, 619-622.	1.9	57
20	Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance. Journal of Urology, 2018, 199, 633-640.	0.4	57
21	Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. Journal of Urology, 2019, 201, 113-119.	0.4	57
22	Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. European Urology, 2014, 66, 841-848.	1.9	56
23	Safety, reliability and accuracy of small renal tumour biopsies: results from a multiâ€institution registry. BJU International, 2017, 119, 543-549.	2.5	56
24	Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 52, 105-116.	7.7	53
25	Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. European Urology, 2020, 78, 460-467.	1.9	53
26	Impact of 5Î±-Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer. European Urology, 2011, 59, 509-514.	1.9	52
27	Robotic surgery basic skills training: Evaluation of a pilot multidisciplinary simulation-based curriculum. Canadian Urological Association Journal, 2013, 7, 430.	0.6	52
28	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 309-321.	1.9	51
29	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	7.1	49
30	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	1.9	49
31	Cryotherapy and radiofrequency ablation: pathophysiologic basis and laboratory studies. Current Opinion in Urology, 2003, 13, 187-191.	1.8	45
32	Canadian guidelines for the management of the small renal mass (SRM). Canadian Urological Association Journal, 2015, 9, 160.	0.6	45
33	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Canadian Urological Association Journal, 2014, 8, 24.	0.6	44
34	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy NaÃ¯ve Men: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 1085-1093.	0.4	44
35	Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. Journal of Urology, 2018, 200, 104-113.	0.4	41
36	Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management. World Journal of Urology, 2019, 37, 437-443.	2.2	41

#	Article	IF	Citations
37	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. Journal of Urology, 2017, 197, 75-83.	0.4	39
38	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. European Urology, 2020, 78, 731-742.	1.9	39
39	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 486.e1-486.e7.	1.6	37
40	Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer. Annals of Internal Medicine, 2017, 167, 341.	3.9	35
41	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. Radiology, 2021, 300, 369-379.	7.3	34
42	Lean Methodology Improves Efficiency in Outpatient Academic Uro-oncology Clinics. Urology, 2014, 83, 992-998.	1.0	33
43	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. Canadian Urological Association Journal, 2017, 11, 182.	0.6	33
44	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. Radiology, 2021, 298, 695-703.	7.3	33
45	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 386.e7-386.e13.	1.6	31
46	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. Urology, 2016, 93, 77-85.	1.0	31
47	The Association Between Vasectomy and Prostate Cancer. JAMA Internal Medicine, 2017, 177, 1273.	5.1	31
48	CUA guideline on the management of cystic renal lesions. Canadian Urological Association Journal, 2017, 11, 66.	0.6	30
49	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer â€“ phase 1 trial. European Radiology, 2018, 28, 4281-4287.	4.5	30
50	miR-10b is a prognostic marker in clear cell renal cell carcinoma. Journal of Clinical Pathology, 2017, 70, 854-859.	2.0	29
51	Active Surveillance in Small Renal Masses in the Elderly: A Literature Review. European Urology Focus, 2017, 3, 340-351.	3.1	29
52	Identifying the use and barriers to the adoption of renal tumour biopsy in the management of small renal masses. Canadian Urological Association Journal, 2018, 12, 260-266.	0.6	27
53	Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma. Human Pathology, 2015, 46, 673-680.	2.0	25
54	Multilocular Cystic Renal Cell Carcinoma: Pathological T Staging Makes No Difference to Favorable Outcomes and Should be Reclassified. Journal of Urology, 2016, 196, 1350-1355.	0.4	25

#	Article	IF	Citations
55	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 486.e17-486.e23.	1.6	25
56	Development and external validation of a biopsyâ€derived nomogram to predict risk of ipsilateral extraprostatic extension. BJU International, 2017, 120, 76-82.	2.5	23
57	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. Urology, 2014, 83, 81-87.	1.0	22
58	The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy. Journal of Urology, 2014, 192, 714-720.	0.4	22
59	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. Journal of Urology, 2018, 199, 906-914.	0.4	22
60	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. Journal of Urology, 2018, 199, 1182-1187.	0.4	22
61	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. Journal of Urology, 2018, 200, 283-291.	0.4	22
62	A miRNA-based classification of renal cell carcinoma subtypes by PCR andin situhybridization. Oncotarget, 2018, 9, 2092-2104.	1.8	22
63	Chronic Kidney Disease in Patients With Renal Cell Carcinoma. Advances in Chronic Kidney Disease, 2014, 21, 91-95.	1.4	21
64	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal, 2019, 13, 307-314.	0.6	21
65	Searching for prognostic biomarkers for small renal masses in the urinary proteome. International Journal of Cancer, 2020, 146, 2315-2325.	5.1	21
66	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. BJU International, 2020, 125, 525-530.	2.5	21
67	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. European Urology, 2022, 81, 576-585.	1.9	21
68	Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. Pharmacological Research, 2016, 113, 468-474.	7.1	19
69	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. Journal of Urology, 2016, 196, 1645-1650.	0.4	19
70	The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study. European Urology, 2017, 72, 379-386.	1.9	19
71	Prognostic urinary miRNAs for the assessment of small renal masses. Clinical Biochemistry, 2020, 75, 15-22.	1.9	18
72	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. Journal of Urology, 2019, 201, 284-291.	0.4	18

#	Article	IF	Citations
73	The uptake of active surveillance for the management of prostate cancer: A population-based analysis. Canadian Urological Association Journal, 2016, 10, 333.	0.6	17
74	Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis. Clinical Genitourinary Cancer, 2017, 15, 300-305.	1.9	17
75	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.6	17
76	Statin use and kidney cancer outcomes: A propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 487.e1-487.e6.	1.6	16
77	Effect of ¹⁸F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology, 2022, 303, 414-422.	7.3	16
78	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nature Communications, 2021, 12, 6248.	12.8	15
79	Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. Canadian Urological Association Journal, 2018, 12, 231-238.	0.6	14
80	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e17-603.e25.	1.6	14
81	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. Journal of Urology, 2021, 206, 1147-1156.	0.4	14
82	Determining Generalizability of the Canadian Kidney Cancer information system (CKCis) to the Entire Canadian Kidney Cancer Population. Canadian Urological Association Journal, 2020, 14, E499-E506.	0.6	13
83	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e1-603.e7.	1.6	13
84	The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: Results from a large population-based cohort. Canadian Urological Association Journal, 2020, 14, 174-181.	0.6	13
85	Active surveillance in patients with a PSA >10 ng/mL. Canadian Urological Association Journal, 2014, 8, 702.	0.6	12
86	Surveillance of Small Renal Masses. Urology, 2016, 98, 8-13.	1.0	12
87	Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass. American Journal of Pathology, 2019, 189, 2366-2376.	3.8	12
88	Pfilates and Hypopressives for the Treatment of Urinary Incontinence After Radical Prostatectomy: Results of a Feasibility Randomized Controlled Trial. PM and R, 2020, 12, 55-63.	1.6	12
89	Virtual care for prostate cancer survivorship: protocol for an evaluation of a nurse-led algorithm-enhanced virtual clinic implemented at five cancer centres across Canada. BMJ Open, 2021, 11, e045806.	1.9	12
90	UPDATE â€“ 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. Canadian Urological Association Journal, 2021, 16, E184-96.	0.6	12

#	Article	IF	Citations
91	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. Canadian Urological Association Journal, 2014, 8, 47.	0.6	11
92	Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights. Canadian Urological Association Journal, 2015, 9, 267.	0.6	11
93	Medication use and kidney cancer risk: AÂpopulation-based study. European Journal of Cancer, 2017, 83, 203-210.	2.8	11
94	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity scorematched cohort. Canadian Urological Association Journal, 2017, 11, 41.	0.6	11
95	Psychological distress and lifestyle disruption in low-risk prostate cancer patients: Comparison between active surveillance and radical prostatectomy. Journal of Psychosocial Oncology, 2018, 36, 159-174.	1.2	11
96	Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. Molecular Oncology, 2018, 12, 1673-1688.	4.6	11
97	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. European Urology Open Science, 2020, 22, 61-73.	0.4	11
98	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. Journal of Urology, 2021, 205, 78-85.	0.4	11
99	Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. British Journal of Radiology, 2022, 95, 20210414.	2.2	11
100	High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial. Applied Physiology, Nutrition and Metabolism, 2021, 46, 1535-1544.	1.9	11
101	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. World Journal of Urology, 2020, 38, 2547-2554.	2.2	10
102	Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. European Urology Focus, 2021, 7, 582-588.	3.1	10
103	Association between metformin medication, genetic variation and prostate cancer risk. Prostate Cancer and Prostatic Diseases, 2021, 24, 96-105.	3.9	10
104	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). Canadian Urological Association Journal, 2020, 15, E81-9.	0.6	10
105	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
106	Impact of ¹⁸F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer. Radiology, 2022, 304, 600-608.	7.3	10
107	Routine small renal mass needle biopsy should be adopted. Nature Reviews Urology, 2014, 11, 548-549.	3.8	9
108	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. Journal of Urology, 2016, 195, 307-312.	0.4	9

#	Article	IF	Citations
109	Critical appraisal of the application of propensity score methods in the urology literature. BJU International, 2017, 120, 873-880.	2.5	9
110	Medication use and kidney cancer survival: A populationâ€based study. International Journal of Cancer, 2018, 142, 1776-1785.	5.1	9
111	Magnetic resonance imaging diagnosis of prostate cancer: promise and caution. Cmaj, 2019, 191, E1177-E1178.	2.0	9
112	Hospital Quality Metrics for Radical Cystectomy: Disease Specific and Correlated to Mortality Outcomes. Journal of Urology, 2019, 202, 490-497.	0.4	9
113	A Prospective Randomized Controlled Trial of Irrigation â€œBag Squeezeâ€•to Manage Pain for Patients Undergoing Flexible Cystoscopy. Journal of Urology, 2020, 204, 1012-1018.	0.4	9
114	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. Journal of Urology, 2020, 204, 1187-1194.	0.4	9
115	Health-related quality of life in robotic versus open radical prostatectomy. Canadian Urological Association Journal, 2015, 9, 179.	0.6	9
116	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 836.e19-836.e27.	1.6	9
117	Management of Small Renal Mass: An Opportunity to Address a Growing Problem in Early Stage Kidney Cancer. European Urology, 2015, 68, 416-417.	1.9	8
118	Diabetes and kidney cancer outcomes: a propensity score analysis. Endocrine, 2017, 55, 470-477.	2.3	8
119	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. Canadian Urological Association Journal, 2017, 11, 232-7.	0.6	8
120	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2019, 104, 61-66.	0.8	8
121	[¹⁸F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	1.9	8
122	Associations between selfâ€reported physical activity, quality of life, and emotional wellâ€being in men with prostate cancer on active surveillance. Psycho-Oncology, 2020, 29, 1044-1050.	2.3	8
123	Quantifying the â€œAssistant Effectâ€•in Robotic-Assisted Radical Prostatectomy (RARP): Measures of Technical Performance. Journal of Surgical Research, 2021, 260, 307-314.	1.6	8
124	Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study. Journal of Urology, 2019, 202, 1159-1165.	0.4	8
125	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. European Radiology, 2022, 32, 7544-7554.	4.5	8
126	Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: long-term oncologic outcomes. Current Opinion in Urology, 2008, 18, 180-184.	1.8	7

#	Article	IF	Citations
127	Should Prebiopsy Multiparametric Magnetic Resonance Imaging be Offered to All Biopsy-naÃ¯ve Men Undergoing Prostate Biopsy?. European Urology, 2016, 69, 426-427.	1.9	7
128	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 240.e13-240.e20.	1.6	7
129	Canadian consensus algorithm for erectile rehabilitation following prostate cancer treatment. Canadian Urological Association Journal, 2018, 13, 239-245.	0.6	7
130	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patientsâ€™ and urologic oncologistsâ€™ perspectives. Canadian Urological Association Journal, 2018, 12, E210-8.	0.6	7
131	Statin use and time to progression in men on active surveillance for prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 509-515.	3.9	7
132	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. European Urology Oncology, 2019, 2, 88-96.	5.4	7
133	Causal Mediation Analysis for Standardized Mortality Ratios. Epidemiology, 2019, 30, 532-540.	2.7	7
134	Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis . Cancer Management and Research, 2019, Volume 11, 10043-10050.	1.9	7
135	Renal Function Outcomes Following Radical or Partial Nephrectomy for Localized Renal Cell Carcinoma: Should Urologists Rely on Preoperative Variables to Predict Renal Function in the Long Term?. European Urology, 2019, 75, 773-774.	1.9	7
136	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. Journal of Urology, 2020, 204, 476-482.	0.4	7
137	Creating patient-centered radiology reports to empower patients undergoing prostate magnetic resonance imaging. Canadian Urological Association Journal, 2020, 15, 108-113.	0.6	7
138	Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 814228.	2.8	7
139	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. Journal of Urology, 2014, 192, 1088-1093.	0.4	6
140	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. Canadian Urological Association Journal, 2016, 10, 424.	0.6	6
141	Re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403â€“6. European Urology, 2017, 71, e45-e46.	1.9	6
142	The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer. Canadian Urological Association Journal, 2017, 11, 167.	0.6	6
143	Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. American Journal of Pathology, 2019, 189, 2046-2060.	3.8	6
144	Metformin Use and Kidney Cancer Survival Outcomes. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 275-284.	1.3	6

#	Article	IF	Citations
145	Needle Tract Seeding Following Renal Tumor Biopsy: Scarcely a Concern or a Concern to Scare?. European Urology, 2019, 75, 868-870.	1.9	6
146	Challenges Interpreting Chemoprevention Studies Using Observational Data. Journal of Clinical Oncology, 2018, 36, 628-629.	1.6	5
147	Influence of physical activity on active surveillance discontinuation in men with low-risk prostate cancer. Cancer Causes and Control, 2019, 30, 1009-1012.	1.8	5
148	Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases. Journal of Clinical Pathology, 2019, 72, 363-367.	2.0	5
149	Management of complex renal cysts in Canada: results of a survey study. BMC Urology, 2020, 20, 47.	1.4	5
150	Natural history of untreated kidney cancer. World Journal of Urology, 2021, 39, 2825-2829.	2.2	5
151	A systematic review and meta-analysis of unplanned hospital visits and re-admissions following radical prostatectomy for prostate cancer. Canadian Urological Association Journal, 2021, 15, E531-E544.	0.6	5
152	Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. Journal of Urology, 2021, 205, 1303-1309.	0.4	5
153	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. Urology, 2021, 153, 147-155.	1.0	5
154	Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. BMJ Open, 2019, 9, e025662.	1.9	4
155	Constructing inverse probability weights for institutional comparisons in healthcare. Statistics in Medicine, 2020, 39, 3156-3172.	1.6	4
156	Predictive Value of In Vivo MR Spectroscopy With Semilocalization by Adiabatic Selective Refocusing in Differentiating Clear Cell Renal Cell Carcinoma From Other Subtypes. American Journal of Roentgenology, 2020, 214, 817-824.	2.2	4
157	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. Prostate, 2021, 81, 286-294.	2.3	4
158	Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 371.e17-371.e25.	1.6	4
159	Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice. Journal of Urology, 2018, 199, 251-256.	0.4	3
160	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. Canadian Urological Association Journal, 2018, 13, 250-255.	0.6	3
161	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 576.e11-576.e16.	1.6	3
162	Causal variance decompositions for institutional comparisons in healthcare. Statistical Methods in Medical Research, 2020, 29, 1972-1986.	1.5	3

#	Article	IF	Citations
163	What are the limits of focal therapy for localized prostate cancer? For: GG3-5 may be considered. European Urology Focus, 2020, 6, 201-202.	3.1	3
164	Long-term outcomes after radical or partial nephrectomy for T1a renal cell carcinoma: A population-based study. Canadian Urological Association Journal, 2020, 14, 392-397.	0.6	3
165	Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care. European Urology Oncology, 2021, 4, 494-497.	5.4	3
166	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.6	3
167	Treatment on active surveillance of small renal masses: Progression vs. preference. Canadian Urological Association Journal, 2021, 16, .	0.6	3
168	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. Urology, 2014, 84, 1073-1080.	1.0	2
169	Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology. Clinical Genitourinary Cancer, 2016, 14, 226-230.	1.9	2
170	Active Surveillance Discussion for Low-risk Prostate Cancer: Patientsâ€™ Preferences and Counseling Techniques. European Urology, 2017, 71, 872-873.	1.9	2
171	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 604.e17-604.e24.	1.6	2
172	Case â€' Foamy high-grade prostatic intraepithelial neoplasia: A false positive for prostate cancer on multiparametric magnetic resonance imaging?. Canadian Urological Association Journal, 2018, 12, E256-9.	0.6	2
173	Low Testosterone and Prostate Cancer: Is the Protection Real?. European Urology, 2018, 74, 595-596.	1.9	2
174	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. Journal of Urology, 2018, 200, 1056-1061.	0.4	2
175	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database. Canadian Urological Association Journal, 2019, 14, 24-30.	0.6	2
176	Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. European Urology, 2020, 78, 927-929.	1.9	2
177	Canadian Update on Surgical Procedures (CUSP) Urology Group consensus for intraoperative hemostasis during minimally invasive partial nephrectomy. Canadian Urological Association Journal, 2020, 14, E387-E393.	0.6	2
178	18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. Current Oncology, 2021, 28, 3251-3258.	2.2	2
179	National consensus quality indicators to assess quality of care for active surveillance in low-risk prostate cancer: An evidence-informed modified Delphi survey of Canadian urologists/radiation oncologists. Canadian Urological Association Journal, 2021, 16, .	0.6	2
180	Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. Urology, 2022, , .	1.0	2

#	Article	IF	Citations
181	Exploring the value of using patient-oriented MRI reports in clinical practice â€" a pilot study. Supportive Care in Cancer, 2022, 30, 6857-6876.	2.2	2
182	A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System. Journal of Urology, 2022, 208, 804-812.	0.4	2
183	Appendix for: The uptake of active surveillance for the management of prostate cancer: A population-based analysis. Canadian Urological Association Journal, 2016, 10, 342.	0.6	1
184	Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. CMAJ Open, 2017, 5, E834-E841.	2.4	1
185	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 702-709.	0.8	1
186	Uncoupling Diagnosis and Treatment of Incidentally Imaged Renal Masses. JAMA Internal Medicine, 2018, 178, 727.	5.1	1
187	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. Canadian Urological Association Journal, 2020, 15, 132-137.	0.6	1
188	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. European Urology Open Science, 2020, 21, 1-4.	0.4	1
189	Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology, 2021, , .	1.0	1
190	Does gender influence morbidity or mortality in the surgical treatment of renal masses?. Canadian Urological Association Journal, 2014, 8, 311.	0.6	1
191	Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.. Journal of Clinical Oncology, 2012, 30, 30-30.	1.6	1
192	Cost-Effectiveness Analysis of Negative Pressure Wound Therapy to Prevent Surgical Site Infection after Elective Colorectal Surgery. Diseases of the Colon and Rectum, 2021, Publish Ahead of Print, .	1.3	1
193	UPDATE â€" 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging â€" Summary of changes. Canadian Urological Association Journal, 2021, 16, 86-87.	0.6	1
194	A Novel Metric for Hospital Quality in Kidney Cancer Surgery: A Veterans Affairs National Health System Validation of Concept. Urology Practice, 2022, 9, 237-245.	0.5	1
195	Assessing the effects of radiation on the small bowel. Canadian Urological Association Journal, 2013, 7, 449.	0.6	0
196	Editorial Comment. Journal of Urology, 2017, 197, 1013-1013.	0.4	0
197	Learning from Our Past Mistakes: A Call for Randomized Controlled Trials in Localized Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 453-454.	5.4	0
198	Reply By Authors. Journal of Urology, 2021, 205, 84-85.	0.4	0

#	Article	IF	Citations
199	Reply by Authors. Journal of Urology, 2021, 206, 1156.	0.4	0
200	Optimizing the management of patients with small renal masses in a Canadian context: A Markov decision-analysis model. Canadian Urological Association Journal, 2021, 16, .	0.6	0
201	Improving outcomes through the development of quality indicators in renal cell cancer.. Journal of Clinical Oncology, 2012, 30, 422-422.	1.6	0
202	Highâ€dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. FASEB Journal, 2012, 26, 388.5.	0.5	0
203	A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.. Journal of Clinical Oncology, 2012, 30, e15118-e15118.	1.6	0
204	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.. Journal of Clinical Oncology, 2017, 35, 42-42.	1.6	0
205	The impact of pre-cancer (Ca) diagnosis (Dx) psychiatric utilization (PU) on survival in patients with solid organ ca: A population analysis in Ontario, Canada.. Journal of Clinical Oncology, 2018, 36, e22144-e22144.	1.6	0
206	A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.. Journal of Clinical Oncology, 2019, 37, 161-161.	1.6	0
207	Reply by Authors. Journal of Urology, 2019, 202, 1165-1165.	0.4	0
208	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.4	0
209	Reply by Authors. Journal of Urology, 2020, 204, 1194-1194.	0.4	0
210	Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0